2009-2011
Postdoctoral studies
CRCHUM, Hôpital Notre-Dame, Institut du Cancer de Montreal
Departement de Biologie moléculaire, Université de Montreal
Supervisor : Dr Richard Bertrand
2005-2008
Postdoctoral studies
Department of Radiation Oncology, School of Medicine
Stanford, University
Supervisor: Dr Amato J. Giaccia
1999-2004
Doctorate in biochemistry (PhD)
Laboratoire de Médecine Moléculaire,
Université du Québec à Montréal (UQAM),
Supervisor: Dr Richard Béliveau
1997-1999
Master in chemistry (Biochemistry) (M.Sc)
Université du Québec à Montréal
Supervisor: Dr Diana A. Averill-Bates
1994-1997
Bachelor in biochemistry (B.Sc)
Université du Québec à Montréal
Funding :
2014-2019
Canadian Institutes for Health Research
2012-2014
Cancer Research Society
2012-2015
KRESCENT New Investigator
2012-2015
NB Health Research Foundation
2012-2015
NB Innovation Foundation
Dr Sandra Turcotte is Assistant Professor at the Université de Moncton and Researcher in Residency at the Atlantic Cancer Research Institute. She completed her PhD in Biochemistry at the Université du Québec à Montréal and Post-doctoral Fellowships at Stanford University in California and at the CRCHUM in Montreal. Dr Turcotte joined the Université de Moncton and ACRI in 2011 with a Research Chair from the Canadian Cancer Society New Brunswick. She is also recipient of a KRESCENT (Kidney Research Scientist Core Education and National Training program) New Investigator award (2012-2015).
Dr Turcotte is member of professional organization such as the Canadian Society of Nephrology and different associations and network such as the Beatrice Hunter Cancer Research Institute and the Kidney Cancer Research Network of Canada. She is also active in grant and scientific journal reviews, and teaching activities. She developed collaborations with national provincial researchers including some of her colleagues at the Université and ACRI.
Research Interests:
Kidney Cancer, clear cell Renal Cell Carinoma
Targeted therapy, synthetic lethality
Autophagy, lysosome
Translational research
Dr Turcotte's research interests focus on kidney cancer to develop targeted therapy based on synthetic lethality. Her studies identify a small molecule that target the loss of the von Hippel-Lindau (VHL) tumor suppressor gene by inducing autophagy. Her laboratory uses a variety of methods from genomic to metabolomic to study the role of autophagy in renal cancer cells. This work aim to transfer knowledge form laboratory bench to bedside to treat patient with kidney cancer.
